13 unchanged sentences
001-33678 
+Added: Form of Certificate of Designation for the Series C Preferred Stock
Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020
1 unchanged sentence
Form of November 2021 Warrant
+Added: Form of Amended July 2020 Warrant
+Added: Form of November 2021 Warrant (as amended)
+Added: Form of September 2022 Warrant (2020 participants)
+Added: Form of September 2022 Warrant for (2021 participants)
+Added: Form of Series A-1 Long-Term Warrant
+Added: Form of Series A-2 Short-Term Warrant
+Added: Form of 2020 Reprice Letter Agreement, dated September 9, 2022
+Added: Form of 2021 Reprice Letter Agreement, dated September 9, 2022
+Added: Form of Securities Purchase Agreement, dated September 9, 2022
+Added: Form of Registration Rights Agreement
+Added: Form of Participant Voting Commitment
+Added: Form of Additional Voting Commitment
+Added: Form of Leak-Out Agreement
Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)
Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)
−Removed: Certification by the Chief Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
−Removed: Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
+Added: Certification by the Chief Executive Officer  
+Added: of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18  
+Added: Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18  
Inline XBRL Instance Document
5 unchanged sentences
The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments)
+Added: * Certain confidential portions of this exhibit were omitted by means of marking such portions with brackets because the confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
+Added: ** These documents are not currently effective and will be entered into and become effective only if the 2022 Private Placement is completed.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: August 11, 2022
+Added: November 14, 2022
/s/   Justin Hall 
2 unchanged sentences
(principal executive officer)
−Removed: August 11, 2022
+Added: November 14, 2022
/s/   Andrew Jones 
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.